New publication - Attana’s technology was applied in the development of antibody fragments, which potentially could be used in future cancer tumor targeting.
In a new paper published in Nature Communications by the group of Prof. Maurice at University Medical Center Utrecht, single chain antibody fragments that block cellular signaling and thus potentially can be used for future tumor targeting were developed. Attana’s technology was used to select the most promising candidates.The development of some cancer types is associated with increased expression of Wnt receptors. Therapeutic targeting of these receptors is thus a promising treatment. In this paper, antibody fragments, so called single-